Registry · REGN
Does Regeneron support Israel?
Regeneron Pharmaceuticals, Inc.
Regeneron does business in Israel — we found records of its operations there, but no record of donations, aid, or a public statement of support. Every claim below links to its source.
Filed under: Pharma & healthcare companies · Companies that support Israel
Background
Regeneron's documented ties to Israel are operational and commercial: it conducts clinical trials at Israeli medical centers (disclosed in its own SEC filings and visible on ClinicalTrials.gov) and it ran a 2016–2020 global drug-development collaboration with Israel-based Teva that has since been discontinued. No record was found of Regeneron corporate donations to the Israeli government or military, to pro-Israel advocacy groups, or of political giving toward Israel-related causes; the review of the Regeneron PAC's recent disbursements found no pro-Israel committee recipients. Personal views or activities of co-founders Leonard Schleifer and George Yancopoulos are personal and are not corporate actions; none are recorded here.
Regeneron 10-Q (SEC EDGAR) ClinicalTrials.gov — Regeneron studies with Israel sites
Timeline of documented records
Documented records
| Type | Date | Amount | Recipient | Sources |
|---|---|---|---|---|
| Operations in Israel | 2024 | — | Clinical-trial sites in Israel (Israeli medical centers) Regeneron runs company-sponsored clinical trials at multiple Israeli hospitals. Its own SEC filings state that "we and our collaborators are currently conducting and may in the future conduct or initiate clinical trials with sites in Russia, Ukraine, and/or Israel." ClinicalTrials.gov lists roughly 19 active Regeneron-led studies with Israel locations; e.g., trial NCT04626635 (REGN7075 + cemiplimab in advanced cancers) enrolls at Sheba Medical Center (Ramat Gan), Soroka (Beersheba), Rambam (Haifa), Shaare Zedek and Hadassah (Jerusalem). This is routine multinational R&D activity conducted in Israel, not a donation or political contribution. | |
| Partnership | 2016-09-20 | $250,000,000 | Teva Pharmaceutical Industries (Israel-headquartered) Regeneron entered a global collaboration with Israel-based Teva to develop and commercialize the pain antibody fasinumab; under the deal Teva paid Regeneron $250 million upfront and the two shared development costs and commercial value. This was a two-way commercial drug-development arrangement (money flowed to Regeneron, not from it), not financial support of Israel. The collaboration was wound down after Regeneron and Teva discontinued the fasinumab program on 2020-08-18 following safety findings. |
Frequently asked questions
Did Regeneron donate money to Israel or Israeli causes?
We have no records of donations. What is on record is commercial activity in Israel (Operations in Israel, Partnership), which is not the same as support — see the records on this page.
Where does this information come from?
Every record on this page links to its source — news reports, official company statements, tax filings, or government records. 6 distinct sources are cited for Regeneron. Our methodology page explains the full verification process.
Sources & citations
Record last updated: 2026-09-25
- Regeneron 10-Q (SEC EDGAR) sec.gov
- ClinicalTrials.gov — NCT04626635 (Israel sites) clinicaltrials.gov
- Regeneron (press release, 2016) investor.regeneron.com
- PR Newswire (2016) prnewswire.com
- Regeneron/Teva fasinumab discontinuation update (2020) newsroom.regeneron.com
- ClinicalTrials.gov — Regeneron studies with Israel sites clinicaltrials.gov